Marked systemic immunomodulatory outcome effects of the supplementations in chronic colitic Winnie was also evidenced by the ability of B. coagulans, PSCF and its synbiotic combination to reduce the elevated CRP in the serum (11.32 ± 0.58, 12.91 ± 0.57 and 12 ± 0.32 μg/mL, respectively) compared to that in unsupplemented Winnie-controls (16.81 ± 0.80 μg/mL) as depicted in Figure 5L. These observations support the substantial immunomodulatory and anti-inflammatory efficacies of the supplementations used in the study to reduce colonic and systemic inflammation in chronic colitis. The gene discussed is CRP; the disease is inflammation.